Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CH Biotech R&D CoTPE:6534 -0.77%93 3-Year EBITDA Growth Rate is 2.00% as of Jun. 2026, which is 17% below its 10-year median of 2.40. GuruFocus rates TPE:6534 with a GF Score™ of 93/100 and a GF Value™ of NT$99.70 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 226 Agriculture companies, CH Biotech R&D Co ranks better than 56.19% on this metric.
During the past 12 months, CH Biotech R&D Co's average EBITDA Per Share Growth Rate was 47.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 2.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 22.50% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 10.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of CH Biotech R&D Co was 45.20% per year. The lowest was -18.70% per year. And the median was 2.40% per year.
CH Biotech R&D Co (TPE:6534) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
CH Biotech R&D Co 3-Year EBITDA Growth Rate Related Terms
TPE:6534 vs CTVA, CF, MOS: 3-Year EBITDA Growth Rate Comparison
For the Agricultural Inputs subindustry, CH Biotech R&D Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CH Biotech R&D Co 3-Year EBITDA Growth Rate vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, CH Biotech R&D Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where CH Biotech R&D Co's 3-Year EBITDA Growth Rate falls into.
CH Biotech R&D Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 2.00% mean?
CH Biotech R&D Co (TPE:6534) has a 3-Year EBITDA Growth Rate of 2.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CH Biotech R&D Co and its competitors. This is 17% below median its historical median of 2.40. According to the industry distribution chart, CH Biotech R&D Co ranks #99 out of 226 companies in the Agriculture industry, placing it in the top 43.8%.
Is CH Biotech R&D Co's 3-Year EBITDA Growth Rate too high?
CH Biotech R&D Co's current 3-Year EBITDA Growth Rate of 2.00% is 17% below median its 10-year median of 2.40. Based on the distribution chart, CH Biotech R&D Co ranks #99 out of 226 companies in the Agriculture industry, which is above the industry midpoint. Overall, CH Biotech R&D Co has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CH Biotech R&D Co's 3-Year EBITDA Growth Rate compare to CTVA and CF?
According to the Agriculture industry distribution chart, CH Biotech R&D Co ranks #99 out of 226 companies for 3-Year EBITDA Growth Rate. This puts CH Biotech R&D Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for an Agriculture company?
A good 3-Year EBITDA Growth Rate depends on the Agriculture industry context. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CH Biotech R&D Co and its competitors. CH Biotech R&D Co's current 3-Year EBITDA Growth Rate is 2.00%, which is 17% below median its own 10-year median of 2.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CH Biotech R&D Co stock overvalued right now?
Based on GuruFocus' analysis, CH Biotech R&D Co (TPE:6534) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$99.70, compared to a current price of NT$89.80 — trading 9.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 2.00%, which is 17% below median its 10-year median of 2.40. CH Biotech R&D Co's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For CH Biotech R&D Co (TPE:6534), the current 3-Year EBITDA Growth Rate is 2.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CH Biotech R&D Co (TPE:6534) Overvalued in 2026?
Based on GuruFocus' analysis, CH Biotech R&D Co stock appears to be undervalued.
The current stock price of NT$89.80 is trading 9.9% below its estimated GF Value™ of NT$99.70.
GuruFocus considers CH Biotech R&D Co to be Modestly Undervalued.
Key valuation signals for TPE:6534:
3-Year EBITDA Growth Rate: 2.00% (17% below median its 10-year median of 2.40)
GF Value™: NT$99.70 vs. price of NT$89.80 (9.9% below fair value)
No single metric tells the full story. See the TPE:6534 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CH Biotech R&D Co Ltd is a Taiwan-based company engaged in the manufacture and sales of fertilizer, as well as providing biotechnology services. It is engaged in the research, development, manufacturing, and sales of proprietary plant growth regulators and specialty micronutrient fertilizers. It offers NutriSync 3D plant growers in the form of boron and molybdenum, NutriSync D liquid formulation for dicot crops, CHB-HS for reducing carbon emissions in crop production, CHB-BB2, fruit quality enhancers, and other related products. The company has one reportable segment, Agricultural Biotechnology. Geographically, it derives maximum revenue from the United States, and the rest from other countries.
93GF Score
Get the complete analysis for TPE:6534
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6534 has been successfully added to your 
